Mozambique suspends commercialization and use of five rapid diagnostic tests

Mozambique's National Medicine Regulatory Authority (Anarme) has suspended the commercialization and use of five rapid diagnostic tests, including those for malaria, HIV, and HIV/Syphilis, citing serious risks of incorrect diagnoses. This decisive action by Anarme, established under Law No. 12/2017, underscores the nation's commitment to public health and robust pharmaceutical and medical device regulation. The suspension, which affects products from manufacturers such as Meril Diagnostics Pvt of India, highlights the critical importance of stringent quality control and regulatory compliance for in vitro diagnostic devices, particularly given the potential for severe public health consequences arising from inaccurate test results for prevalent diseases.

The National Medicine Regulatory Authority (Anarme) of Mozambique has recently taken a significant step to safeguard public health by suspending the commercialization and use of five rapid diagnostic tests (RDTs) within the country. This measure, prompted by "serious risks" of incorrect diagnoses, impacts crucial tests for diseases such as malaria, Human Immunodeficiency Virus (HIV), and HIV/Syphilis. The affected products include those manufactured by Meril Diagnostics Pvt of India, alongside other unspecified tests like HIVFIND.

Anarme's intervention highlights the critical importance of a vigilant regulatory framework for medical devices, especially in a context where accurate and reliable diagnostics are paramount for effective disease management and public health interventions. The potential for erroneous results from these RDTs poses a substantial threat, ranging from delayed or inappropriate treatment to the misallocation of healthcare resources and the erosion of public trust in diagnostic tools. This article will delve into the legal and regulatory underpinnings of Anarme's authority, analyze the implications of this suspension, and consider the broader landscape of medical device regulation in Mozambique.

The regulatory landscape for medicines and health products in Mozambique is primarily governed by the Lei do Medicamento, Vacinas, Produtos Biológicos e de Saúde para Uso Humano (Law No. 12/2017 of September 8). This landmark legislation established Anarme as a public institution endowed with legal personality and administrative, financial, and patrimonial autonomy. Anarme's mandate is comprehensive, encompassing the regulation, supervision, inspection, sanctioning, and representation of all aspects of the pharmaceutical sector, with a core objective of ensuring the quality, safety, efficacy, and traceability of pharmaceutical products circulating in the country.

Prior to Law No. 12/2017, regulatory responsibilities were managed by the National Directorate of Pharmacy (DNF) under the Ministry of Health, and the previous Lei n.º 4/98 of January 14, 1998, provided the legal foundation for pharmaceutical practices. While the 2017 Law broadly covers "produtos de saúde" (health products), the specific regulation of medical devices, including in vitro diagnostic devices, has seen a significant evolution. Earlier assessments noted a less defined framework for medical devices in Mozambique compared to medicines. However, a more recent Decree, published in May 2023, explicitly regulates the requirements for market authorization (Autorização de Introdução no Mercado – AIM) of health products, herbal and homeopathic medicines, and crucially, "dispositivos médicos e de diagnóstico in vitro" for human use. This Decree, aligned with Law No. 12/2017 and international guidelines from the WHO and SADC, aims to ensure that products commercialized in Mozambique do not pose public health risks.

Anarme's decision to suspend the rapid diagnostic tests is a direct exercise of its powers under Law No. 12/2017, which tasks the authority with establishing a national quality assurance system for medicinal products and an efficient pharmacovigilance system to detect adverse effects and ensure product safety. The "serious risks" of incorrect diagnoses cited by Anarme fall squarely within its mandate to protect public health from substandard or falsified medical products. The suspension of commercialization and use is a critical regulatory tool to prevent further harm when product quality or performance is compromised.

The concerns regarding Meril Diagnostics Pvt of India are not isolated to Mozambique. The National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria issued a "Notice of Concern" (NOC) for several Meril Diagnostics Pvt. Ltd. products, including malaria and HIV tests, following significant violations observed during a World Health Organization (WHO) Prequalification audit of the company's manufacturing facility. This WHO audit concluded that the manufacturer was not operating in compliance with WHO requirements and applicable quality standards, thereby raising serious questions about the quality and safety of their medical devices. This international corroboration lends significant weight to Anarme's concerns and underscores the importance of global regulatory collaboration and adherence to international standards.

The evolving regulatory framework in Mozambique, particularly with the May 2023 Decree, demonstrates a concerted effort to strengthen oversight of medical devices. While historical gaps in specific medical device regulation were noted, the explicit inclusion of "dispositivos médicos e de diagnóstico in vitro" under Anarme's market authorization requirements signifies a maturing regulatory environment. This proactive stance is crucial, especially for RDTs used in the diagnosis of high-burden diseases like HIV and malaria, where timely and accurate results are vital for patient care and disease control. The consequences of inaccurate RDTs can be dire, leading to misdiagnosis, delayed treatment, and potentially contributing to disease transmission or drug resistance.

Comparative practices, such as the European Medicines Agency's (EMA) "Rapid Alert Network" for urgent actions concerning medicinal products due to quality defects, illustrate a global consensus on the necessity of swift regulatory responses to protect public health. Mozambique's alignment with WHO and SADC guidelines, as stated in the May 2023 Decree, further emphasizes its commitment to harmonizing its regulatory practices with international best practices.

Anarme's suspension of these rapid diagnostic tests serves as a stark reminder of the indispensable role of robust regulatory bodies in safeguarding public health. This action not only protects Mozambican citizens from potentially harmful and misleading diagnostic results but also sends a clear message to manufacturers and distributors about the non-negotiable standards of quality and safety required for medical products in the country. The international context provided by the WHO Prequalification audit and NAFDAC's similar concerns regarding Meril Diagnostics further validates Anarme's decisive intervention.

For legal practitioners and entities operating within Mozambique's healthcare sector, this development underscores the critical need for meticulous adherence to national and international regulatory standards for medical devices. Manufacturers and importers must ensure that their products undergo rigorous testing, maintain consistent quality, and comply with all market authorization requirements stipulated by Anarme, particularly under the evolving framework outlined in Law No. 12/2017 and the May 2023 Decree. Continued vigilance, investment in quality assurance, and proactive engagement with regulatory authorities will be essential to navigate this increasingly stringent landscape and ensure the provision of safe and effective healthcare solutions in Mozambique.